Your browser doesn't support javascript.
loading
Alzheimer's disease genetic pathways impact cerebrospinal fluid biomarkers and imaging endophenotypes in non-demented individuals.
Lorenzini, Luigi; Collij, Lyduine E; Tesi, Niccoló; Vilor-Tejedor, Natàlia; Ingala, Silvia; Blennow, Kaj; Foley, Christopher; Frisoni, Giovanni B; Haller, Sven; Holstege, Henne; van der van der Lee, Sven; Martinez-Lage, Pablo; Marioni, Riccardo E; McCartney, Daniel L; O' Brien, John; Oliveira, Tiago Gil; Payoux, Pierre; Reinders, Marcel; Ritchie, Craig; Scheltens, Philip; Schwarz, Adam J; Sudre, Carole H; Waldman, Adam D; Wolz, Robin; Chatelat, Gael; Ewers, Michael; Wink, Alle Meije; Mutsaerts, Henk J M M; Gispert, Juan Domingo; Visser, Pieter Jelle; Tijms, Betty M; Altmann, Andre; Barkhof, Frederik.
Afiliación
  • Lorenzini L; Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centre, Vrije Universiteit, Amsterdam, The Netherlands.
  • Collij LE; Amsterdam Neuroscience, Brain Imaging, Amsterdam, The Netherlands.
  • Tesi N; Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centre, Vrije Universiteit, Amsterdam, The Netherlands.
  • Vilor-Tejedor N; Amsterdam Neuroscience, Brain Imaging, Amsterdam, The Netherlands.
  • Ingala S; Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
  • Blennow K; Amsterdam Neuroscience, Brain Imaging, Amsterdam, The Netherlands.
  • Foley C; Genomics of Neurodegenerative Diseases and Aging, Human Genetics, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Frisoni GB; Delft Bioinformatics Lab, Delft University of Technology, Delft, The Netherlands.
  • Haller S; Barcelonaßeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
  • Holstege H; Universitat Pompeu Fabra, Barcelona, Spain.
  • van der van der Lee S; Centre for Genomic Regulation (CRG), The Barcelona Institute for Science and Technology, Barcelona, Spain.
  • Martinez-Lage P; Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Marioni RE; Department of Radiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
  • McCartney DL; Cerebriu A/S, Copenhagen, Denmark.
  • O' Brien J; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
  • Oliveira TG; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
  • Payoux P; GE Healthcare, Amersham, UK.
  • Reinders M; Laboratory Alzheimer's Neuroimaging & Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
  • Ritchie C; University Hospitals and University of Geneva, Geneva, Switzerland.
  • Scheltens P; CIMC - Centre d'Imagerie Médicale de Cornavin, Geneva, Switzerland.
  • Schwarz AJ; Department of Surgical Sciences, Radiology, Uppsala University, Uppsala, Sweden.
  • Sudre CH; Department of Radiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, P. R. China.
  • Waldman AD; Genomics of Neurodegenerative Diseases and Aging, Human Genetics, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Wolz R; Genomics of Neurodegenerative Diseases and Aging, Human Genetics, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Chatelat G; Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Ewers M; Centro de Investigación y Terapias Avanzadas, Neurología, CITA-Alzheimer Foundation, San Sebastián, Spain.
  • Wink AM; Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
  • Mutsaerts HJMM; Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
  • Gispert JD; Department of Psychiatry, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
  • Visser PJ; Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal.
  • Tijms BM; ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal.
  • Altmann A; Department of Nuclear Medicine, Toulouse University Hospital, Toulouse, France.
  • Barkhof F; ToNIC, Toulouse NeuroImaging Center, University of Toulouse, Inserm, Toulouse, France.
Alzheimers Dement ; 20(9): 6146-6160, 2024 Sep.
Article en En | MEDLINE | ID: mdl-39073684
ABSTRACT

INTRODUCTION:

Unraveling how Alzheimer's disease (AD) genetic risk is related to neuropathological heterogeneity, and whether this occurs through specific biological pathways, is a key step toward precision medicine.

METHODS:

We computed pathway-specific genetic risk scores (GRSs) in non-demented individuals and investigated how AD risk variants predict cerebrospinal fluid (CSF) and imaging biomarkers reflecting AD pathology, cardiovascular, white matter integrity, and brain connectivity.

RESULTS:

CSF amyloidbeta and phosphorylated tau were related to most GRSs. Inflammatory pathways were associated with cerebrovascular disease, whereas quantitative measures of white matter lesion and microstructure integrity were predicted by clearance and migration pathways. Functional connectivity alterations were related to genetic variants involved in signal transduction and synaptic communication.

DISCUSSION:

This study reveals distinct genetic risk profiles in association with specific pathophysiological aspects in predementia stages of AD, unraveling the biological substrates of the heterogeneity of AD-associated endophenotypes and promoting a step forward in disease understanding and development of personalized therapies. HIGHLIGHTS Polygenic risk for Alzheimer's disease encompasses six biological pathways that can be quantified with pathway-specific genetic risk scores, and differentially relate to cerebrospinal fluid and imaging biomarkers. Inflammatory pathways are mostly related to cerebrovascular burden. White matter health is associated with pathways of clearance and membrane integrity, whereas functional connectivity measures are related to signal transduction and synaptic communication pathways.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Biomarcadores / Péptidos beta-Amiloides / Endofenotipos / Enfermedad de Alzheimer Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Alzheimers Dement Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Biomarcadores / Péptidos beta-Amiloides / Endofenotipos / Enfermedad de Alzheimer Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Alzheimers Dement Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos